Virbac

In the first half Virbac reported sales of €768m (+7.4% currency-adjusted) and quarterly sales of €384m, slightly above the LSEG consensus estimate of €381m. Growth was driven mainly by volume and product mix (about 5.4 percentage points); price adjustments contributed roughly 2 percentage points. The company confirmed its 2026 targets: sales growth of 5.5–7.5% and an adjusted operating margin of around 17%. » Más en de.investing.com

Virbac reports currency- and portfolio-adjusted sales growth of 7.7% in Q1, driven by strong North America business (+20.7%) and gains in international markets (+9.1%). Volume increases contributed around 6 percentage points to growth, price adjustments about 2%; exchange rates weighed with roughly -5.5%. The Thyronorm acquisition added about 1%; pet products and livestock showed double-digit and strong increases, while regulatory delays weighed on other businesses. Virbac confirms its full-year guidance of +5.5–7.5% sales growth at constant exchange rates, expects an adjusted EBITA margin of around 17% and cash generation of about €80m with capex of around €125m. » Más en de.investing.com

Virbac reports 2025 revenue of €1,464.7m (+8.7% nominal, +7.9% organic) and adjusted EBIT of €234.4m with a margin of 16.0%. Currency losses weighed on revenue and EBIT, while R&D spending rose to a record level (€115.1m) and the pipeline includes around 40 prioritized projects. North America was the strongest growth region at +14.7%; pets continue to account for the majority of sales (58.8%). The Thyronorm acquisition strengthens the endocrinology platform; management expects 2026 organic revenue growth of 5.5–7.5% and an adjusted EBIT margin of around 17%. » Más en de.investing.com